Joinn Laboratories Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 2,649

Employees

  • Stock Symbol
  • 603127

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $4.83
  • (As of Friday Closing)

Joinn Laboratories General Information

Description

Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • No. 5, Rongjing East Street
  • Beijing Economic and Technological Development Area
  • Beijing, 100176
  • China
+86 010
Primary Industry
Laboratory Services (Healthcare)
Stock Exchange
SHG
Corporate Office
  • No. 5, Rongjing East Street
  • Beijing Economic and Technological Development Area
  • Beijing, 100176
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Joinn Laboratories Stock Performance

As of 20-Nov-2026, Joinn Laboratories’s stock price is $4.83. Its current market cap is $3.31B with 749M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.83 $5.29 $3.78 - $8.24 $3.31B 749M 35.5M $0.22

Joinn Laboratories Financials Summary

As of 30-Sep-2026, Joinn Laboratories has a trailing 12-month revenue of $270M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,752,304 3,118,787 1,145,456 1,870,251
Revenue 269,934 230,503 281,283 335,905
EBITDA 171,677 56,325 18,616 70,263
Net Income 166,382 41,417 10,323 56,113
Total Assets 1,692,770 1,383,782 1,287,127 1,414,547
Total Debt 5,533 3,086 8,352 9,794
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Joinn Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Joinn Laboratories‘s full profile, request access.

Request a free trial

Joinn Laboratories Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Joinn Laboratories Investments & Acquisitions (6)

Joinn Laboratories’s most recent deal was a Merger/Acquisition with Yingmao Biotechnology. The deal was made on 29-Apr-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Yingmao Biotechnology 29-Apr-2022 Merger/Acquisition Animal Husbandry
Weimei Biotechnology 01-Apr-2022 Merger/Acquisition Laboratory Services (Healthcare)
Yinmore Group 01-Jan-2022 Merger/Acquisition Conglomerates
JOINN Biologics 31-Aug-2021 Early Stage VC Other Pharmaceuticals and Biotechnology
Biomere 10-Dec-2019 Merger/Acquisition Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Joinn Laboratories ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

21.19 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Joinn Laboratories’s complete esg history, request access »

Joinn Laboratories Exits (2)

Joinn Laboratories’s most recent exit was on 29-Apr-2022 from Yingmao Biotechnology. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Yingmao Biotechnology 29-Apr-2022 Completed
Weimei Biotechnology 01-Apr-2022 Merger/Acquisition Completed
To view Joinn Laboratories’s complete exits history, request access »

Joinn Laboratories Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Yinmore Group Kunming, China 1997
Biomere Worcester, MA 1996

Joinn Laboratories FAQs

  • When was Joinn Laboratories founded?

    Joinn Laboratories was founded in 1995.

  • Where is Joinn Laboratories headquartered?

    Joinn Laboratories is headquartered in Beijing, China.

  • What is the size of Joinn Laboratories?

    Joinn Laboratories has 2,649 total employees.

  • What industry is Joinn Laboratories in?

    Joinn Laboratories’s primary industry is Laboratory Services (Healthcare).

  • Is Joinn Laboratories a private or public company?

    Joinn Laboratories is a Public company.

  • What is Joinn Laboratories’s stock symbol?

    The ticker symbol for Joinn Laboratories is 603127.

  • What is the current stock price of Joinn Laboratories?

    As of 20-Nov-2026 the stock price of Joinn Laboratories is $4.83.

  • What is the current market cap of Joinn Laboratories?

    The current market capitalization of Joinn Laboratories is $3.31B.

  • What is Joinn Laboratories’s current revenue?

    The trailing twelve month revenue for Joinn Laboratories is $270M.

  • What is Joinn Laboratories’s annual earnings per share (EPS)?

    Joinn Laboratories’s EPS for 12 months was $0.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process